Literature DB >> 12918187

Regression of hypertensive nephropathy during three years of optimal blood pressure control.

Heidi Puttinger1, Afschin Soleiman, Rainer Oberbauer.   

Abstract

Hypertensive nephropathy is among the leading causes of end-stage renal disease. Once renal function is severely impaired, the effects of strict control of blood pressure on the recovery of renal function remain elusive. Published case series suggest that optimal control of blood pressure results in regression of renal failure to some extent. In the present case of biopsy-proven hypertensive nephropathy we show that renal function can substantially improve over time if blood pressure is optimally controlled. Glomerula filtration rate continuously improved in our patient from 20 ml/min at presentation to 80 ml/min over a period of three years using a fivefold antihypertensive regimen. Hypertensive retinopathy regressed from stage III to stage I, and left ventricular hypertrophy decreased from an initial septum thickness of 19 mm to 12 mm within that period of time. This case clearly illustrates that optimal control of blood pressure is mandatory in patients with pre-terminal renal failure due to hypertensive nephropathy. Such intervention can lead to a regression of hypertension-associated end-organ injury.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12918187     DOI: 10.1007/bf03040436

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  9 in total

1.  Some different types of essential hypertension: their course and prognosis.

Authors:  N M Keith; H P Wagener; N W Barker
Journal:  Am J Med Sci       Date:  1974-12       Impact factor: 2.378

2.  The regression of hypertensive retinopathy.

Authors:  R P Rutstein; A P Cullen; D D Forte
Journal:  J Am Optom Assoc       Date:  1978-04

3.  Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.

Authors:  Kristian Wachtell; Jonathan N Bella; Jens Rokkedal; Vittorio Palmieri; Vasilios Papademetriou; Björn Dahlöf; Tapio Aalto; Eva Gerdts; Richard B Devereux
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

4.  "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis.

Authors:  R D Toto; H C Mitchell; R D Smith; H C Lee; D McIntire; W A Pettinger
Journal:  Kidney Int       Date:  1995-09       Impact factor: 10.612

5.  Minoxidil treatment of malignant hypertension. Recovery of renal function.

Authors:  F C Luft; R Bloch; J J Szwed; C M Grim; C E Grim
Journal:  JAMA       Date:  1978-10-27       Impact factor: 56.272

6.  Reversible renal failure in malignant hypertension.

Authors:  F T Cordingley; N F Jones; A J Wing; P J Hilton
Journal:  Clin Nephrol       Date:  1980-08       Impact factor: 0.975

7.  Reversal of lesions of diabetic nephropathy after pancreas transplantation.

Authors:  P Fioretto; M W Steffes; D E Sutherland; F C Goetz; M Mauer
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

8.  Partial recovery of renal function in black patients with apparent end-stage renal failure due to primary malignant hypertension.

Authors:  S H James; A M Meyers; F J Milne; S G Reinach
Journal:  Nephron       Date:  1995       Impact factor: 2.847

9.  Recovery in malignant hypertension presenting as acute renal failure.

Authors:  C G Isles; A McLay; J M Jones
Journal:  Q J Med       Date:  1984
  9 in total
  3 in total

1.  [Remission of chronic kidney diseases. A realistic goal?].

Authors:  Gert Mayer
Journal:  Wien Klin Wochenschr       Date:  2003-07-15       Impact factor: 1.704

2.  Accuracy of retinal changes in predicting microalbuminuria among elderly hypertensive patients: a cross-sectional study from a teaching hospital in South India.

Authors:  Ghanshyam Palamaner Subash Shantha; Emmanuel Bhaskar; Anita A Kumar; Varun Sundaram; Arul Senghor; Porchelvan Swaminathan; Manjunath Sundaresan; Yadav Srinivasan; Georgi Abraham
Journal:  Int Urol Nephrol       Date:  2008-09-03       Impact factor: 2.370

Review 3.  [Sympathetic overactivity and the kidney].

Authors:  Antje Habicht; Bruno Watschinger
Journal:  Wien Klin Wochenschr       Date:  2003-09-30       Impact factor: 2.275

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.